Glutamic Acid Decarboxylase (GAD) Autoantibody

The Glutamic Acid Decarboxylase (GAD) Autoantibody assay (also known as anti‑GAD or GAD65 antibody testing) is used to semiquantitatively assess autoimmunity against glutamate decarboxylase to support the diagnosis of autoimmune (type 1) diabetes mellitus and to help differentiate type 1 from type 2 diabetes. In relatives of patients with type 1 diabetes, positivity informs risk stratification for future disease. The test also assists in evaluating neurologic syndromes associated with anti‑GAD immunity, including stiff‑person (Moersch–Woltman) syndrome, autoimmune cerebellar ataxia, epilepsy, myasthenia gravis, and paraneoplastic encephalitis.

Glutamic acid decarboxylase catalyzes gamma‑aminobutyric acid (GABA) synthesis and is expressed in neurons and pancreatic beta cells. Anti‑GAD autoantibodies are present in approximately 95% of patients at the time of type 1 diabetes diagnosis and indicate ongoing immune‑mediated beta‑cell destruction, thereby aiding distinction of autoimmune type 1 diabetes from type 2 diabetes. Anti‑GAD responses generally persist longer than islet cell cytoplasmic antibodies and are detected more often in adults with type 1 diabetes than in children. Seroconversion may precede the onset of hyperglycemia. In relatives of patients with type 1 diabetes, isolated anti‑GAD positivity confers an estimated 10‑year risk increase of about 20%, while the presence of two or more islet autoantibodies predicts approximately 90% risk over 10 years. In persons without a family history, a single positive anti‑GAD result does not substantially change background population risk. Autoimmune endocrinopathies—Graves disease, celiac disease, and primary adrenal insufficiency—occur more frequently in type 1 diabetes; when anti‑GAD is positive, additional testing for associated autoimmune conditions is recommended. Markedly elevated anti‑GAD titers, often exceeding levels observed in type 1 diabetes by more than 100‑fold, are linked to autoimmune neurologic disorders, particularly stiff‑person syndrome, autoimmune cerebellar ataxia, epilepsy, myasthenia gravis, paraneoplastic encephalitis, and Lambert–Eaton syndrome. Anti‑GAD antibodies are also detected in approximately 8% of healthy individuals, some of whom harbor autoantibodies suggestive of autoimmune thyroid or gastric disease, indicating a predisposition to Hashimoto thyroiditis, thyrotoxicosis, or pernicious anemia.